Literature DB >> 33554335

Hypoalbuminemia and clinical adverse events in children with COVID-19.

Lorenzo Loffredo1, Andrea Campana2, Nicole Olivini2, Nicola Cotugno2, Paolo Palma2, Alessandra Oliva3, Guglielmo Salvatori4, Anna Maria Zicari5, Francesco Violi1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33554335      PMCID: PMC8013663          DOI: 10.1002/jmv.26856

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


× No keyword cloud information.
To the Editor, Hypoalbuminemia is considered a predictor of adverse outcomes in critically ill children and in adults affected by COVID‐19. , In particular, former studies reported that hypoalbuminemia is a predictor of vascular disease and death. , Hypoalbuminemia has been reported in children with a severe form of COVID‐19. Conversely, it is unclear whether children with moderate/mild form of COVID‐19 have reduced albumin values and if there is an association with inflammatory or infective events. Thus, we wanted to explore this issue in this study. This study was performed at Bambino Gesù Children's Hospital located in Rome (Italy) and in the dedicated COVID unit. Methods are described in Supporting Information data. Sixty‐three children affected by mild/moderate COVID‐19 were consecutively recruited at the Bambino Gesù Children's Hospital in Rome. Clinical characteristics and symptoms at admission are reported in Table 1.
Table 1

Clinical and laboratory characteristics on admission in patients selected according to the presence of clinical events or not during hospitalization

Children with events during hospitalizationChildren without events during hospitalization p
N 1647
Age8.9 ± 56.6 ± 5.149
Male/female8/827/20.736
Weight (kg)42 ± 2230 ± 21.119
Height (cm)1.41 ± 0.421.20 ± 0.36.136
Hs‐CRP (mg/L)* 4.4 [0.13–3.7]0.2 [0.06–0.3] <.001
Albumin (g/dl)3.7 ± 0.84.5 ± 0.4 <.001
Symptoms at admission
Fever1524 .002
Diarrhea111.131
Rhinitis04.295
Arthralgias33.145
Skin manifestation21.092
Tachycardia and chest pain12.746
Convulsions12.746
Cough310.829

Expressed as median and IQR.

Abbreviation: hs‐CRP, high‐sensitivity C reactive protein.

Clinical and laboratory characteristics on admission in patients selected according to the presence of clinical events or not during hospitalization Expressed as median and IQR. Abbreviation: hs‐CRP, high‐sensitivity C reactive protein. The median in‐hospital stay was 7 days (interquartile range [IQR] = 5–11). Sixteen patients experienced clinical events: seven multisystem inflammatory syndromes, four pneumonia, three myocardial involvement (troponin increased with ST‐segment elevation (n = 1), troponin increase alone (n = 1), pericarditis (n = 1)), and two urinary tract infections. All these clinical events occurred in symptomatic children. Compared to patients who did not experience clinical events, those with clinical events had lower serum albumin (Figure 1A), higher high‐sensitivity C reactive protein (hs‐CRP) and presence of fever at admission (see Table 1). Furthermore, serum albumin correlated with hs‐CRP levels (R = −0.616, p < .001) in all the population. The highest and lowest levels of hs‐CRP and serum albumin were detected in the children with multisystem inflammatory syndrome. Compared to the other children who manifested a clinical event (n = 9), those with multisystem inflammatory syndrome (n = 7) had lower serum albumin (median = 4.2, IQR = 3.9–4.3 g/dl vs. median = 2.7 g/dl, IQR = 2.5–4.1 g/dl, p = .04, respectively) (Figure 1B) and higher, even if not significant, hs‐CRP levels (median = 0.25 mg/L, IQR = 0.07–4.94 mg/L vs. median =  5.3 mg/L, IQR = 0.66–14.5 mg/L, p = .07, respectively). A significant difference for albumin and hs‐CRP values was also observed when children with multisystem inflammatory syndrome were compared to children without clinical events (albumin:median = 2.7g/dl, IQR = 2.5–4.1 g/dl vs. median = 4.6 g/dl, IQR = 4.2–4.8 g/dl, p = .001 [Figure 1B] and hs‐CRP median = 5.3 mg/L, IQR = 0.66–14.5 mg/L vs. median = 0.06 mg/L, IQR = 0.03–0.26 mg/L, p < .001, respectively). Furthermore, compared to children without clinical events, those who experienced clinical events without multisystem inflammatory syndrome had lower serum albumin (p = .04, Figure 1B) and higher hs‐CRP (p = .03) levels.
Figure 1

(A) Box and whisker plots of serum albumin in children with (white) and without (dark grey) events. *p < .05. (B) Box and whisker plots of serum albumin in children without clinical events (dark grey), multisystem inflammatory syndrome (white), and with other clinical events (light grey). *p < .05

(A) Box and whisker plots of serum albumin in children with (white) and without (dark grey) events. *p < .05. (B) Box and whisker plots of serum albumin in children without clinical events (dark grey), multisystem inflammatory syndrome (white), and with other clinical events (light grey). *p < .05 In this study, we showed that among children with moderate/mild COVID‐19 those with clinical complications involving lungs and other organs had lower albumin serum levels compared to those without clinical events. Furthermore, children with COVID‐19 and multisystem inflammatory syndrome have the lowest values of serum albumin. These values could be a precocious marker of this potentially lethal condition. COVID‐19 infection is characterized by a cytokine storm, which entails systemic inflammation and eventually vascular damage predisposing to thrombosis and death. Albumin is an acute‐phase protein, which is reduced during infections because of its anti‐inflammatory and antioxidant properties. Its reduction, however, hampers the body's anti‐inflammatory defense, thus promoting inflammation and eventually leading to multiorgan damage. In this context, it is interesting to note that albumin possesses both anticoagulant and antiplatelet activities. Thereby its reduction has been suggested to favor thrombosis. The present study reinforces this concept as we found an inverse correlation between serum albumin and hs‐CRP, a marker of systemic inflammation, as well as with clinical outcomes involving lung, heart, and kidney. In accordance with a previous study, we did not find hypoalbuminemia in children with moderate or mild COVID‐19; however, in our population, children with potentially life‐threatening conditions, such as those with multisystem inflammatory syndrome, had hypoalbuminemia. This different behavior could depend on the inflammatory status, which is likely more severe in patients with multisystem inflammatory syndrome. These children have hypoalbuminemia as do those with severe COVID‐19 requiring intensive care, another condition characterized by high inflammatory status and albumin levels less than 3.0 g/dl. A previous study found low levels of albumin (mean = 3.4 g/dl) in children with COVID‐19 and multisystem inflammatory syndrome. Our study supports and extends this previous one indicating that hypoalbuminemia occurs in children with multisystem inflammatory syndrome and that low albumin was associated with clinical events. Another finding of this study is the increased hs‐CRP levels in patients with clinical complications. This is in accordance with previous studies that reported laboratory markers (as CRP, procalcitonin, and LDH) to be associated with COVID‐19 severity in children. In conclusion, this study points to lower albumin values as a wake‐up call for clinical complications including multisystem inflammatory syndrome, in children with mild/moderate COVID‐19. Supporting information. Click here for additional data file.
  11 in total

1.  Is Albumin Predictor of Mortality in COVID-19?

Authors:  Francesco Violi; Roberto Cangemi; Giulio Francesco Romiti; Giancarlo Ceccarelli; Alessandra Oliva; Francesco Alessandri; Matteo Pirro; Pasquale Pignatelli; Miriam Lichtner; Anna Carraro; Francesco Cipollone; Damiano D'ardes; Francesco Pugliese; Claudio Maria Mastroianni
Journal:  Antioxid Redox Signal       Date:  2020-06-22       Impact factor: 8.401

2.  Hypoalbuminemia, Coagulopathy, and Vascular Disease in COVID-19.

Authors:  Francesco Violi; Giancarlo Ceccarelli; Roberto Cangemi; Francesco Alessandri; Gabriella D'Ettorre; Alessandra Oliva; Daniele Pastori; Lorenzo Loffredo; Pasquale Pignatelli; Franco Ruberto; Mario Venditti; Francesco Pugliese; Claudio Maria Mastroianni
Journal:  Circ Res       Date:  2020-06-08       Impact factor: 17.367

3.  Hypoalbuminemia in critically ill children.

Authors:  Ira N Horowitz; Kenneth Tai
Journal:  Arch Pediatr Adolesc Med       Date:  2007-11

Review 4.  Human serum albumin and its relation with oxidative stress.

Authors:  Mustafa Erinç Sitar; Seval Aydin; Ufuk Cakatay
Journal:  Clin Lab       Date:  2013       Impact factor: 1.138

5.  Multisystem Inflammatory Syndrome in U.S. Children and Adolescents.

Authors:  Leora R Feldstein; Erica B Rose; Steven M Horwitz; Jennifer P Collins; Margaret M Newhams; Mary Beth F Son; Jane W Newburger; Lawrence C Kleinman; Sabrina M Heidemann; Amarilis A Martin; Aalok R Singh; Simon Li; Keiko M Tarquinio; Preeti Jaggi; Matthew E Oster; Sheemon P Zackai; Jennifer Gillen; Adam J Ratner; Rowan F Walsh; Julie C Fitzgerald; Michael A Keenaghan; Hussam Alharash; Sule Doymaz; Katharine N Clouser; John S Giuliano; Anjali Gupta; Robert M Parker; Aline B Maddux; Vinod Havalad; Stacy Ramsingh; Hulya Bukulmez; Tamara T Bradford; Lincoln S Smith; Mark W Tenforde; Christopher L Carroll; Becky J Riggs; Shira J Gertz; Ariel Daube; Amanda Lansell; Alvaro Coronado Munoz; Charlotte V Hobbs; Kimberly L Marohn; Natasha B Halasa; Manish M Patel; Adrienne G Randolph
Journal:  N Engl J Med       Date:  2020-06-29       Impact factor: 91.245

Review 6.  Laboratory abnormalities in children with mild and severe coronavirus disease 2019 (COVID-19): A pooled analysis and review.

Authors:  Brandon Michael Henry; Stefanie W Benoit; Maria Helena Santos de Oliveira; Wan Chin Hsieh; Justin Benoit; Rami A Ballout; Mario Plebani; Giuseppe Lippi
Journal:  Clin Biochem       Date:  2020-05-27       Impact factor: 3.281

7.  Hypercoagulation and Antithrombotic Treatment in Coronavirus 2019: A New Challenge.

Authors:  Francesco Violi; Daniele Pastori; Roberto Cangemi; Pasquale Pignatelli; Lorenzo Loffredo
Journal:  Thromb Haemost       Date:  2020-04-29       Impact factor: 5.249

8.  Clinical and Immune Features of Hospitalized Pediatric Patients With Coronavirus Disease 2019 (COVID-19) in Wuhan, China.

Authors:  Huan Wu; Hongmin Zhu; Chunhui Yuan; Cong Yao; Wei Luo; Xin Shen; Jun Wang; Jianbo Shao; Yun Xiang
Journal:  JAMA Netw Open       Date:  2020-06-01

9.  Hyperinflammatory shock in children during COVID-19 pandemic.

Authors:  Shelley Riphagen; Xabier Gomez; Carmen Gonzalez-Martinez; Nick Wilkinson; Paraskevi Theocharis
Journal:  Lancet       Date:  2020-05-07       Impact factor: 79.321

View more
  4 in total

1.  CURB-65 plus hypoalbuminemia: a new score system for prediction of the in-hospital mortality risk in patients with SARS-CoV-2 pneumonia.

Authors:  Alessandra Oliva; Cristian Borrazzo; Maria Teresa Mascellino; Ambrogio Curtolo; Dania Al Ismail; Francesca Cancelli; Gioacchino Galardo; Tommaso Bucci; Giancarlo Ceccarelli; Gabriella d'Ettorre; Francesco Pugliese; Claudio M Mastroianni; Mario Venditti
Journal:  Infez Med       Date:  2021-09-10

2.  Clinical course of Coronavirus Disease-19 in patients with haematological malignancies is characterized by a longer time to respiratory deterioration compared to non-haematological ones: results from a case-control study.

Authors:  A Oliva; A Curtolo; L Volpicelli; F Cancelli; C Borrazzo; F Cogliati Dezza; G Marcelli; F Gavaruzzi; S Di Bari; P Ricci; O Turriziani; C M Mastroianni; M Venditti
Journal:  Infection       Date:  2022-07-03       Impact factor: 7.455

3.  Autopsy findings of pediatric COVID-19: a systematic review.

Authors:  Gilbert Sterling Octavius; Jeremiah Hilkiah Wijaya; Alexa Ovilia Tan; Michelle Patricia Muljono; Shally Chandra; Andry Juliansen
Journal:  Egypt J Forensic Sci       Date:  2022-07-14

4.  Different rates of conjunctivitis in COVID-19 eastern and western hospitalized patients: a meta-analysis.

Authors:  Lorenzo Loffredo; Alessia Fallarino; Aurora Paraninfi; Fernanda Pacella; Elena Pacella; Alessandra Oliva; Francesco Violi
Journal:  Intern Emerg Med       Date:  2021-11-09       Impact factor: 5.472

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.